evidence/gaps
Cochrane · systematic review · CD012039

Pharmacotherapy for hypertension‐induced left ventricular hypertrophy

Leache, L, Gutiérrez-Valencia, M, Finizola, RM, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library

HypertensionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Antihypertensive therapy versus placebo or no treatment for hypertension‐induced left ventricular hypertrophy

Population: adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
5 questions
OutcomeEffectEvidenceStatus / GRADE
All‐cause mortality
Antihypertensive therapy vs placebo or no treatment
RR 1.02 [0.74, 1.4]3 studies · 930 participantsVery low
Downgraded: imprecision, indirectness
Cardiovascular events
Antihypertensive therapy vs placebo or no treatment
RR 1.09 [0.77, 1.55]3 studies · 930 participantsVery low
Downgraded: imprecision, indirectness
Total serious adverse events
Antihypertensive therapy vs placebo or no treatment
RR 1.02 [0.89, 1.16]3 studies · 930 participantsVery low
Downgraded: risk of bias, imprecision, indirectness
Hospitalisation for heart failure
Antihypertensive therapy vs placebo or no treatment
RR 0.82 [0.57, 1.17]2 studies · 915 participantsVery low
Downgraded: imprecision, indirectness
Withdrawal due to adverse events
Antihypertensive therapy vs placebo or no treatment
RR 3.09 [1.69, 5.66]1 study · 522 participantsVery low
Downgraded: imprecision, indirectness, publication bias